-
Subject Areas on Research
-
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.
-
A negative charge in transmembrane segment 1 of domain II of the cockroach sodium channel is critical for channel gating and action of pyrethroid insecticides.
-
A new irreversibly inhibited form of xanthine oxidase from ethylisonitrile.
-
A nuclear factor-kappaB inhibitor BAY11-7082 inhibits interactions between human endothelial cells, T cells, and monocytes.
-
A randomized controlled trial comparing changes in fitness with or without supervised exercise in patients initiated on enzalutamide and androgen deprivation therapy for non-metastatic castration-sensitive prostate cancer (EXTEND).
-
ALSUntangled 48: Perampanel (Fycompa).
-
ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer.
-
Activation by odorants of a multistate cation channel from olfactory cilia.
-
Activation of extracellular signal-regulated kinase (ERK) in G2 phase delays mitotic entry through p21CIP1.
-
Activation of protein kinase C inhibits human keratinocyte migration.
-
Adjuvant radiation therapy, androgen deprivation, and docetaxel for high-risk prostate cancer postprostatectomy: Results of NRG Oncology/RTOG study 0621.
-
Alternative splicing of an insect sodium channel gene generates pharmacologically distinct sodium channels.
-
An alanine in segment 3 of domain III (IIIS3) of the cockroach sodium channel contributes to the low pyrethroid sensitivity of an alternative splice variant.
-
An important role of a pyrethroid-sensing residue F1519 in the action of the N-alkylamide insecticide BTG 502 on the cockroach sodium channel.
-
An interdomain interaction of the androgen receptor is required for its aggregation and toxicity in spinal and bulbar muscular atrophy.
-
Androgen deprivation therapy and depression in men with prostate cancer treated with definitive radiation therapy.
-
Androgen receptor antagonism drives cytochrome P450 17A1 inhibitor efficacy in prostate cancer.
-
Aromatase inhibitors for breast cancer: proven efficacy across the spectrum of disease.
-
Association Between New Unconfirmed Bone Lesions and Outcomes in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide: Secondary Analysis of the PREVAIL and AFFIRM Randomized Clinical Trials.
-
Batrachotoxin, pyrethroids, and BTG 502 share overlapping binding sites on insect sodium channels.
-
Bi-directional migration of lens epithelial cells in a physiological electrical field.
-
Biochemical recurrence after definitive prostate cancer therapy. Part II: treatment strategies for biochemical recurrence of prostate cancer.
-
Biochemical recurrence of prostate cancer.
-
Blockade of the extracellular signal-regulated kinase pathway by U0126 attenuates neuronal damage following circulatory arrest.
-
Cellular mechanisms of sex determination in the red-eared slider turtle, Trachemys scripta.
-
Characterization of Isavuconazole serum concentrations after enteral feeding tube administration in a hospitalized cohort: A case series.
-
Characterization of deltamethrin metabolism by rat plasma and liver microsomes.
-
Circulating Tumor Cell Chromosomal Instability and Neuroendocrine Phenotype by Immunomorphology and Poor Outcomes in Men with mCRPC Treated with Abiraterone or Enzalutamide.
-
Circulating Tumor Cell Genomic Evolution and Hormone Therapy Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer.
-
Clinical Outcomes of Chemotherapy Naïve Men with Metastatic Castration Resistant Prostate Cancer and Low Baseline Prostate Specific Antigen Treated with Enzalutamide vs Placebo.
-
Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide.
-
Clinical outcomes and survival surrogacy studies of prostate-specific antigen declines following enzalutamide in men with metastatic castration-resistant prostate cancer previously treated with docetaxel.
-
Co-regulation of nuclear respiratory factor-1 by NFkappaB and CREB links LPS-induced inflammation to mitochondrial biogenesis.
-
Comparative field evaluation of combinations of long-lasting insecticide treated nets and indoor residual spraying, relative to either method alone, for malaria prevention in an area where the main vector is Anopheles arabiensis.
-
Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer.
-
Copper-Catalyzed 1,2-Aminocyanation of Unactivated Alkenes via Cyano Migration.
-
Copy Number Loss of 17q22 Is Associated with Enzalutamide Resistance and Poor Prognosis in Metastatic Castration-Resistant Prostate Cancer.
-
Currently approved and emerging oral therapies in multiple sclerosis: An update for the ophthalmologist.
-
Cyanogenic glycosides and menisdaurin from Guazuma ulmifolia, Ostrya virgininana, Tiquilia plicata and Tiquilia canescens.
-
DHX15 is up-regulated in castration-resistant prostate cancer and required for androgen receptor sensitivity to low DHT concentrations.
-
Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance.
-
Development and validation of a prognostic model for overall survival in chemotherapy-naïve men with metastatic castration-resistant prostate cancer.
-
Development and validation of circulating tumour cell enumeration (Epic Sciences) as a prognostic biomarker in men with metastatic castration-resistant prostate cancer.
-
Developmental origin of peripheral ciliary band neurons in the sea urchin embryo.
-
Differential effects of TipE and a TipE-homologous protein on modulation of gating properties of sodium channels from Drosophila melanogaster.
-
Disruption of dystroglycan-laminin interactions modulates water uptake by astrocytes.
-
Docetaxel chemotherapy in metastatic castration-resistant prostate cancer: cost of care in Medicare and commercial populations.
-
Drug susceptibility and resistance mutations after first-line failure in resource limited settings.
-
ERK MAP kinase activation in superficial spinal cord neurons induces prodynorphin and NK-1 upregulation and contributes to persistent inflammatory pain hypersensitivity.
-
Economic Outcomes in Patients with Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate Plus Prednisone.
-
Effect of Enzalutamide plus Androgen Deprivation Therapy on Health-related Quality of Life in Patients with Metastatic Hormone-sensitive Prostate Cancer: An Analysis of the ARCHES Randomised, Placebo-controlled, Phase 3 Study.
-
Effect of a fluvalinate-resistance-associated sodium channel mutation from varroa mites on cockroach sodium channel sensitivity to fluvalinate, a pyrethroid insecticide.
-
Effect of individual and community-level bed net usage on malaria prevalence among under-fives in the Democratic Republic of Congo.
-
Effects of dietary exposure to the pyrethroid pesticide esfenvalerate on medaka (Oryzias latipes).
-
Effects of downregulated HDAC6 expression on the proliferation of lung cancer cells.
-
Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAIL.
-
Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer by Pattern of Metastatic Spread: ARCHES Post Hoc Analyses.
-
Efficacy of enzalutamide in subgroups of men with metastatic hormone-sensitive prostate cancer based on prior therapy, disease volume, and risk.
-
Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I.
-
Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I.
-
Electric fields and MAP kinase signaling can regulate early wound healing in lens epithelium.
-
Enantioselective Intermolecular Pd-Catalyzed Hydroalkylation of Acyclic 1,3-Dienes with Activated Pronucleophiles.
-
Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial.
-
Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study.
-
Enzalutamide in metastatic prostate cancer before chemotherapy.
-
Enzalutamide versus abiraterone acetate for the treatment of men with metastatic castration-resistant prostate cancer.
-
Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial.
-
Enzalutamide with androgen deprivation therapy in Japanese men with metastatic hormone-sensitive prostate cancer: A subgroup analysis of the phase III ARCHES study.
-
Erk/MAP kinase signaling pathway and neuroendocrine differentiation of non-small-cell lung cancer.
-
Estrogen excess associated with novel gain-of-function mutations affecting the aromatase gene.
-
Estrogen protects against intracranial aneurysm rupture in ovariectomized mice.
-
Estrogen receptor-β ligand treatment after disease onset is neuroprotective in the multiple sclerosis model.
-
Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole.
-
Evaluating the extent of intramolecular charge transfer in the excited states of rhenium(I) donor-acceptor complexes with time-resolved vibrational spectroscopy.
-
Exploring the Clinical Benefit of Docetaxel or Enzalutamide After Disease Progression During Abiraterone Acetate and Prednisone Treatment in Men With Metastatic Castration-Resistant Prostate Cancer.
-
Extracellular signal-regulated kinase plays an essential role in hypertrophic agonists, endothelin-1 and phenylephrine-induced cardiomyocyte hypertrophy.
-
Factor Xa induces tissue factor expression in endothelial cells by P44/42 MAPK and NF-κB-dependent pathways.
-
Finally, a Successful Randomized Trial for GVHD.
-
Finasteride and bicalutamide as primary hormonal therapy in patients with advanced adenocarcinoma of the prostate.
-
Fine scale spatial investigation of multiple insecticide resistance and underlying target-site and metabolic mechanisms in Anopheles gambiae in central Côte d'Ivoire.
-
Five-year Survival Prediction and Safety Outcomes with Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer from the PREVAIL Trial.
-
Genomic Drivers of Poor Prognosis and Enzalutamide Resistance in Metastatic Castration-resistant Prostate Cancer.
-
Glutathione S-transferase-mediated chlorothalonil metabolism in liver and gill subcellular fractions of channel catfish.
-
Identification of a nonbasic, nitrile-containing cathepsin K inhibitor (MK-1256) that is efficacious in a monkey model of osteoporosis.
-
Impact of enzalutamide on patient-reported fatigue in patients with prostate cancer: data from the pivotal clinical trials.
-
Importance of the stress kinase p38alpha in mediating the direct cytotoxic effects of the thalidomide analogue, CPS49, in cancer cells and endothelial cells.
-
Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer.
-
Improved surgical outcomes for breast cancer patients receiving neoadjuvant aromatase inhibitor therapy: results from a multicenter phase II trial.
-
Increased survival with enzalutamide in prostate cancer after chemotherapy.
-
Indirect Comparison of Darolutamide versus Apalutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer.
-
Induction of Neuroinflammation and Neurotoxicity by Synthetic Hemozoin.
-
Inhibition of mitogen-activated protein kinase and phosphatidylinositol 3-kinase activity in MCF-7 cells prevents estrogen-induced mitogenesis.
-
Inhibition of the androgen receptor induces a novel tumor promoter, ZBTB46, for prostate cancer metastasis.
-
Interleukin-1beta elevates cyclooxygenase-2 protein level and enzyme activity via increasing its mRNA stability in human endometrial stromal cells: an effect mediated by extracellularly regulated kinases 1 and 2.
-
Isavuconazole Treatment of Cryptococcosis and Dimorphic Mycoses.
-
Isavuconazole for treatment of rare invasive fungal diseases.
-
Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis.
-
Isavuconazole treatment for rare fungal diseases and for invasive aspergillosis in patients with renal impairment: Challenges and lessons of the VITAL trial.
-
Jakinibs for the treatment of immune dysregulation in patients with gain-of-function signal transducer and activator of transcription 1 (STAT1) or STAT3 mutations.
-
Janus kinase inhibitors for atopic dermatitis: a promising treatment modality.
-
Joint acute toxicity of esfenvalerate and diazinon to larval fathead minnows (Pimephales promelas).
-
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).
-
Kinetics of interaction of disopyramide with the cardiac sodium channel: fast dissociation from open channels at normal rest potentials.
-
LINC00675 activates androgen receptor axis signaling pathway to promote castration-resistant prostate cancer progression.
-
Leflunomide for polyomavirus type BK nephropathy.
-
Letrozole in the treatment of breast cancer.
-
Ligand-specific dynamics of the androgen receptor at its response element in living cells.
-
Linking prostate cancer cell AR heterogeneity to distinct castration and enzalutamide responses.
-
Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial.
-
Metastatic Hormone-Sensitive Prostate Cancer: A Review of the Current Treatment Landscape.
-
Mining database for the expression and gene regulation network of JAK2 in skin cutaneous melanoma.
-
Molecular basis of selective resistance of the bumblebee BiNav
1 sodium channel to tau-fluvalinate.
-
Molecular determinants for enzalutamide-induced transcription in prostate cancer.
-
Molecular determinants on the insect sodium channel for the specific action of type II pyrethroid insecticides.
-
N-Myc promotes therapeutic resistance development of neuroendocrine prostate cancer by differentially regulating miR-421/ATM pathway.
-
NFκB-mediated CXCL1 production in spinal cord astrocytes contributes to the maintenance of bone cancer pain in mice.
-
Neoadjuvant comparisons of aromatase inhibitors and tamoxifen: pretreatment determinants of response and on-treatment effect.
-
Novel sodium channel gene mutations in Blattella germanica reduce the sensitivity of expressed channels to deltamethrin.
-
Ontogeny of hepatic and plasma metabolism of deltamethrin in vitro: role in age-dependent acute neurotoxicity.
-
Optimization of 2,4-diarylanilines as non-nucleoside HIV-1 reverse transcriptase inhibitors.
-
Organotypic models of type III interferon-mediated protection from Zika virus infections at the maternal-fetal interface.
-
PET scanning in mild cognitive impairment.
-
PGC-1alpha regulates a HIF2alpha-dependent switch in skeletal muscle fiber types.
-
Pathogenesis of duodenal ulcer. Gastric hyperacidity caused by propionitrile and cysteamine in rats.
-
Pathologic and biologic response to preoperative endocrine therapy in patients with ER-positive ductal carcinoma in situ.
-
Pharmacodynamics of Isavuconazole in a Rabbit Model of Cryptococcal Meningoencephalitis.
-
Phase I/II dose-escalation study of PI3K inhibitors pilaralisib or voxtalisib in combination with letrozole in patients with hormone-receptor-positive and HER2-negative metastatic breast cancer refractory to a non-steroidal aromatase inhibitor.
-
Phase II Trial of Enzalutamide and Androgen Deprivation Therapy with Salvage Radiation in Men with High-risk Prostate-specific Antigen Recurrent Prostate Cancer: The STREAM Trial.
-
Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer.
-
Phase II trial of the PI3 kinase inhibitor buparlisib (BKM-120) with or without enzalutamide in men with metastatic castration resistant prostate cancer.
-
Phase Ib Study of the BET Inhibitor GS-5829 as Monotherapy and Combined with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer.
-
Primary brain tumours in Fischer 344 rats chronically exposed to acrylonitrile in their drinking-water.
-
Primary cytoreductive surgery and adjuvant hormonal monotherapy in women with advanced low-grade serous ovarian carcinoma: Reducing overtreatment without compromising survival?
-
Prognostic Association of Prostate-specific Antigen Decline with Clinical Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Treated with Enzalutamide in a Randomized Clinical Trial.
-
Prospective Evaluation of Clinical Outcomes Using a Multiplex Liquid Biopsy Targeting Diverse Resistance Mechanisms in Metastatic Prostate Cancer.
-
Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study.
-
Prostate-specific antigen dynamics predict individual responses to intermittent androgen deprivation.
-
Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAIL.
-
Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype--ACOSOG Z1031.
-
Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed.
-
Real-world outcomes of second novel hormonal therapy or radium-223 following first novel hormonal therapy for mCRPC.
-
Regulation of the macrophage population in postnatal rat testis.
-
Remission of progressive metastatic castration-resistant prostate cancer during abiraterone therapy following unilateral adrenalectomy for a functioning adrenal adenoma.
-
Reply to M.A.N. Şendur et al and J. Michels.
-
Response and resistance to NF-κB inhibitors in mouse models of lung adenocarcinoma.
-
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.
-
Role of mitogen-activated protein kinase in osteoblast differentiation.
-
Roles of estrogen in the formation of intracranial aneurysms in ovariectomized female mice.
-
Rotational Symmetry of Two Pyrethroid Receptor Sites in the Mosquito Sodium Channel.
-
Ruxolitinib + capecitabine in advanced/metastatic pancreatic cancer after disease progression/intolerance to first-line therapy: JANUS 1 and 2 randomized phase III studies.
-
Ruxolitinib cream for the treatment of patients with alopecia areata: A 2-part, double-blind, randomized, vehicle-controlled phase 2 study.
-
Ruxolitinib for the treatment of steroid refractory pediatric chronic graft-versus-host disease.
-
Ruxolitinib: a new treatment for myelofibrosis.
-
Safety and Efficacy of Ruxolitinib in Patients with Myelofibrosis and Low Platelet Counts (50 - 100 × 109/L): Final Analysis of an Open-Label Phase 2 Study.
-
Safety of concomitant therapy with radium-223 and abiraterone or enzalutamide in a real-world population.
-
Safety of enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: expanded access in North America.
-
Seizure Rates in Enzalutamide-Treated Men With Metastatic Castration-Resistant Prostate Cancer and Risk of Seizure: The UPWARD Study.
-
Selective aromatase inhibition for patients with androgen-independent prostate carcinoma.
-
Self-Assembling Peptide Gels for 3D Prostate Cancer Spheroid Culture.
-
Simultaneous measurement of myocardial perfusion and ventricular function during exercise from a single injection of technetium-99m sestamibi in coronary artery disease.
-
Small-Molecule-Mediated Degradation of the Androgen Receptor through Hydrophobic Tagging.
-
Snail promotes resistance to enzalutamide through regulation of androgen receptor activity in prostate cancer.
-
Sorafenib, a multikinase inhibitor, enhances the response of melanoma to regional chemotherapy.
-
Sphingolipid Metabolic Pathway Impacts Thiazide Diuretics Blood Pressure Response: Insights From Genomics, Metabolomics, and Lipidomics.
-
Spotlight on isavuconazole in the treatment of invasive aspergillosis and mucormycosis: design, development, and place in therapy.
-
Statin and metformin use and outcomes in patients with castration-resistant prostate cancer treated with enzalutamide: A meta-analysis of AFFIRM, PREVAIL and PROSPER.
-
Structure-based design and synthesis of potent, ethylenediamine-based, mammalian farnesyltransferase inhibitors as anticancer agents.
-
Suppression of food intake by glucagon-like peptide-1 receptor agonists: relative potencies and role of dipeptidyl peptidase-4.
-
Survival by race in men with chemotherapy-naive enzalutamide- or abiraterone-treated metastatic castration-resistant prostate cancer.
-
Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate.
-
Synergistic interaction between two cockroach sodium channel mutations and a tobacco budworm sodium channel mutation in reducing channel sensitivity to a pyrethroid insecticide.
-
Syntaxin 6-mediated exosome secretion regulates enzalutamide resistance in prostate cancer.
-
TRPV4 is necessary for trigeminal irritant pain and functions as a cellular formalin receptor.
-
Testosterone with dutasteride, but not anastrazole, improves insulin sensitivity in young obese men: a randomized controlled trial.
-
The Arabidopsis epithiospecifier protein promotes the hydrolysis of glucosinolates to nitriles and influences Trichoplusia ni herbivory.
-
The Effect of Corticosteroids on Prostate Cancer Outcome Following Treatment with Enzalutamide: A Multivariate Analysis of the Phase III AFFIRM Trial.
-
The Evolving Landscape of Frontline Therapy in Chronic Phase Chronic Myeloid Leukemia (CML).
-
The G Protein-Coupled Estrogen Receptor Agonist G-1 Inhibits Nuclear Estrogen Receptor Activity and Stimulates Novel Phosphoproteomic Signatures.
-
The PREVAIL Study: Primary Outcomes by Site and Extent of Baseline Disease for Enzalutamide-treated Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer.
-
The activity of letrozole in patients with advanced or recurrent endometrial cancer and correlation with biological markers--a study of the National Cancer Institute of Canada Clinical Trials Group.
-
The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis.
-
The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers.
-
The distal cytoplasmic domain of the erythropoietin receptor induces granulocytic differentiation in 32D cells.
-
The genetic basis of a plant-insect coevolutionary key innovation.
-
The impact of adjuvant endocrine therapy on reducing the risk of distant metastases in hormone-responsive breast cancer.
-
The impact of enzalutamide on quality of life in men with metastatic hormone-sensitive prostate cancer based on prior therapy, risk, and symptom subgroups.
-
The metabolic regulator ERRα, a downstream target of HER2/IGF-1R, as a therapeutic target in breast cancer.
-
The role of N-cadherin/c-Jun/NDRG1 axis in the progression of prostate cancer.
-
Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistance.
-
Transcriptional profiling of matched patient biopsies clarifies molecular determinants of enzalutamide-induced lineage plasticity.
-
Treating the biochemical recurrence of prostate cancer after definitive primary therapy.
-
Treatment Patterns and Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer in a Real-world Clinical Practice Setting in the United States.
-
Treatment options for patients with prostate cancer who develop metastatic disease after hormonal therapy.
-
Treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin improves fasting islet-cell function in subjects with type 2 diabetes.
-
Twenty years of controversy surrounding combined androgen blockade for advanced prostate cancer.
-
WNT11 expression is induced by estrogen-related receptor alpha and beta-catenin and acts in an autocrine manner to increase cancer cell migration.
-
Whole Genomic Copy Number Alterations in Circulating Tumor Cells from Men with Abiraterone or Enzalutamide-Resistant Metastatic Castration-Resistant Prostate Cancer.
-
Whole-genome analysis informs breast cancer response to aromatase inhibition.
-
Keywords of People